Halmos B, Burke T, Kalyvas C, et al. - In previously untreated non-squamous NSCLC without EGFR/ALK aberrations, researchers performed an indirect comparison between pembrolizumab + chemotherapy vs atezolizumab + chemotherapy+/-bevacizumab in terms of efficacy. They utilized individual patient data from KEYNOTE-021 Cohort G (KN021 G) (pembrolizumab + carboplatin + pemetrexed; N = 59) and KEYNOTE-189 (KN189) (pembrolizumab + pemetrexed + platinum chemotherapy; N = 410) as well as published aggregate data from IMpower 130 (atezolizumab + carboplatin + nab-paclitaxel; N = 451) and IMpower 150 (atezolizumab + carboplatin + paclitaxel + bevacizumab; N = 356) in order to perform a matching-adjusted indirect comparison (MAIC). As per findings of MAIC, pembrolizumab + chemotherapy conferred a significantly better overall survival and progression-free survival (PFS) vs atezolizumab + chemotherapy, and pembrolizumab + chemotherapy provided a significantly better PFS vs atezolizumab + chemotherapy + bevacizumab.